Who makes Hyper insulinemic euglycemic clamp?

Hyper insulinemic euglycemic clamp is developed by King Saud University.

What development phase is Hyper insulinemic euglycemic clamp in?

Hyper insulinemic euglycemic clamp is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Hyper insulinemic euglycemic clamp

King Saud University · FDA-approved active Small molecule Quality 0/100

Hyper insulinemic euglycemic clamp, marketed by King Saud University, is a diagnostic tool used to assess insulin sensitivity in patients. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.

At a glance

Generic name	Hyper insulinemic euglycemic clamp
Sponsor	King Saud University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results